About Gilead Sciences, Inc.
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy. In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences.
2BB score and signals
Gilead Sciences, Inc.’s current 2BB score is 58 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|
| Activity | 54 | Moderate |
| Momentum | 50 | Stable |
| Financial strength | 69 | Strong |
| Quality | 100 | Very Strong |
| Risk | 35 | Low |
Company facts
| CEO | Daniel O'Day |
| Headquarters | Foster City, California, United States |
| Founded | Jun 22, 1987 |
| Employees | 17K |
| 52-week range | $108.46 – $157.27 |
Recent earnings
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|
| 2027-02-08 | — | 2.2357 | — | $8.29B |
| 2026-10-28 | — | 2.1911 | — | $7.94B |
| 2026-08-04 | — | -7.3797 | — | $7.55B |
| 2026-05-07 | 2.03 | 1.9525 | $6.96B | $7.05B |
Related companies
